Ipsen: Phase 3 Trial Shows Positive Survival Results in Pancreatic Ductal Adenocarcinoma

 

• Investigational Onivyde^® (irinotecan liposome injection) in the NALIRIFOX treatment regimen demonstrated statistically significant improvements in overall survival and progression-free survival compared to nab-paclitaxel plus gemcitabine with a manageable safety profile¹
• Results represent a potential advance in an aggressive and difficult-to-treat cancer
• Ipsen plans to file a supplemental New Drug Application with the U.S. Food and Drug Administration

https://www.biospace.com/article/releases/ipsen-presents-phase-iii-napoli-3-trial-of-onivyde-regimen-demonstrating-positive-survival-results-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma-at-asco-gi/